New treatment for osteosarcoma using an immunomodulating peptide
Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human
['FUNDING_SBIR_2'] · PHARMAIN CORPORATION · NIH-10931704
This study is testing a new treatment made from a special peptide that could help kids and teens with osteosarcoma, a type of bone cancer, by boosting their immune response and possibly stopping the cancer from spreading, offering hope for better outcomes alongside current chemotherapy options.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PHARMAIN CORPORATION (nih funded) |
| Locations | 1 site (BOTHELL, UNITED STATES) |
| Trial ID | NIH-10931704 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel immunomodulating peptide aimed at treating osteosarcoma, a common bone cancer in children and adolescents. The approach involves using this peptide to enhance anti-tumor activity and potentially prevent metastasis, which is a significant challenge in current treatments. The research will evaluate the peptide's effectiveness both as a standalone therapy and in combination with existing chemotherapy regimens. Patients may benefit from a new treatment option that could improve survival rates and reduce the risk of cancer spreading.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and adolescents diagnosed with osteosarcoma, particularly those at risk of metastasis.
Not a fit: Patients with osteosarcoma who have already undergone extensive treatment or those with non-responsive tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option that significantly improves survival rates for children with osteosarcoma.
How similar studies have performed: Previous research has shown promising results with similar immunomodulating therapies in cancer treatment, indicating potential for success in this approach.
Where this research is happening
BOTHELL, UNITED STATES
- PHARMAIN CORPORATION — BOTHELL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ALFARO, JOSHUA — PHARMAIN CORPORATION
- Study coordinator: ALFARO, JOSHUA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.